Pfizer has announced it is discontinuing the development of its cholesterol-lowering PCSK9 inhibitor bococizumab. “The totality of clinical information now available for bococizumab, taken together with the evolving treatment and market landscape for lipid-lowering agents, indicates that bococizumab is not likely to provide value to patients, physicians, or shareholders,” said the company in a press ...
Pfizer pulls plug on PCSK9 Inhibitor
By Nicola Garrett
2 Nov 2016